Shares of Beigene Ltd (NASDAQ:BGNE) have received an average rating of “Buy” from the thirteen ratings firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, nine have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $185.82.
Several research analysts recently commented on BGNE shares. Leerink Swann started coverage on shares of Beigene in a report on Monday, September 24th. They issued an “outperform” rating and a $215.00 target price on the stock. Zacks Investment Research downgraded shares of Beigene from a “hold” rating to a “sell” rating in a report on Tuesday, July 10th. CLSA started coverage on shares of Beigene in a report on Wednesday, September 19th. They issued a “buy” rating and a $160.75 target price on the stock. Maxim Group reiterated a “buy” rating and issued a $215.00 target price on shares of Beigene in a report on Thursday, September 20th. Finally, Cowen reiterated a “buy” rating on shares of Beigene in a report on Sunday, October 14th.
In related news, Director Bros. Advisors Lp Baker acquired 5,814,100 shares of the company’s stock in a transaction dated Thursday, August 2nd. The shares were bought at an average price of $108.00 per share, for a total transaction of $627,922,800.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Xiaodong Wang sold 3,449 shares of the business’s stock in a transaction dated Monday, August 13th. The stock was sold at an average price of $158.77, for a total transaction of $547,597.73. The disclosure for this sale can be found here. Insiders sold a total of 14,129 shares of company stock worth $2,389,512 in the last quarter. Insiders own 14.10% of the company’s stock.
Large investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC increased its holdings in shares of Beigene by 5,558.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 679 shares of the company’s stock worth $104,000 after purchasing an additional 667 shares during the period. Rockefeller Capital Management L.P. bought a new position in shares of Beigene during the 2nd quarter worth about $135,000. K.J. Harrison & Partners Inc bought a new position in shares of Beigene during the 3rd quarter worth about $207,000. Virtu Financial LLC bought a new position in shares of Beigene during the 2nd quarter worth about $212,000. Finally, Northern Trust Corp bought a new position in shares of Beigene during the 1st quarter worth about $302,000. Institutional investors own 77.75% of the company’s stock.
Beigene stock opened at $110.69 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 8.14 and a quick ratio of 8.10. Beigene has a 1-year low of $77.54 and a 1-year high of $220.10.
Beigene (NASDAQ:BGNE) last announced its earnings results on Thursday, August 9th. The company reported ($2.92) EPS for the quarter, missing the consensus estimate of ($2.12) by ($0.80). The firm had revenue of $52.80 million during the quarter, compared to the consensus estimate of $22.53 million. Beigene had a negative return on equity of 24.14% and a negative net margin of 75.19%. The business’s revenue was up 5279999900.0% compared to the same quarter last year. During the same quarter last year, the business earned ($1.52) EPS. As a group, research analysts forecast that Beigene will post -10.86 earnings per share for the current year.
BeiGene, Ltd. develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.
Further Reading: Leveraged Buyout (LBO)
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.